Chronic Itp 2

Article

Learn About Chronic ITP In the first of a series of video presentation, Dr. Lou Aledort introduces an informative presentation on Nplate® for use in patients with chronic ITP. Learn how Nplate® mimics the body's natural process of platelet production in patients with ITP.

Learn About Chronic ITP
In the first of a series of video presentation, Dr. Lou Aledort introduces an informative presentation on Nplate® for use in patients with chronic ITP. Learn how Nplate® mimics the body's natural process of platelet production in patients with ITP.

 

 


A discussion of the evolving perspective on ITP by David Kuter, MD, DPhil, Professor of Medicine, Harvard Medical School.


This monograph provides a detailed profile of Nplate®, including:


A detailed explanation of Nplate® dosing and administration.

 

Nplate® NEXUS Program
The Nplate® NEXUS (Network of Experts Understanding and Supporting Nplate® and Patients) Program connects you with Nplate® access, support, education, and safety monitoring.

Nplate® Patient Website
Nplate.com provides patients with information about ITP and details about Nplate® including how it works, how it differs from other ITP treatments, clinical trial results in patients with chronic ITP, how it is administered, and information on access and reimbursement. It also includes the Conversation Companion, a helpful self-assessment tool for patients and their doctors. To learn more, please visit www.Nplate.com today.

 

M50120-E-3

Indication

 Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.

IMPORTANT SAFETY INFORMATION

Serious adverse reactions associated with Nplate® in clinical studies were bone marrow reticulin deposition and worsening thrombocytopenia after Nplate® discontinuation. Additional risks include Bone Marrow Fibrosis, Thrombotic/Thromboembolic Complications, Lack or Loss of Response to Nplate®, Hematological Malignancies and Progression of Malignancy in Patients with a Pre-existing Hematological Malignancy or Myelodysplastic Syndrome (MDS).

Please see additional Important Safety Information and full Prescribing Information and Medication Guide for more information about Nplate®.

 

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content